Blogs The Glucagon Receptor (GCGR)

The Glucagon Receptor (GCGR)

What is the Glucagon Receptor?

The Glucagon Receptor (GCGR) is pivotal in glucose metabolism and energy homeostasis. As a member of the G protein-coupled receptor (GPCR) family, GCGR mediates the effects of glucagon, a peptide hormone secreted by the pancreas that regulates blood glucose levels. GCGR is predominantly expressed in the liver but also found in the kidneys, heart, adipose tissue, and brain, highlighting its widespread physiological influence.1

The Glucagon receptor blog image

GCGR’s Role in Metabolic Regulation

GCGR’s activation triggers a cascade of intracellular signaling events that are crucial for maintaining glucose and energy balance. Upon glucagon binding, GCGR stimulates glycogenolysis and gluconeogenesis in the liver, processes that increase glucose production during fasting states.2 Key functions of GCGR include:

  • Glycogenolysis and Gluconeogenesis: GCGR activation stimulates the breakdown of glycogen into glucose and the synthesis of glucose from non-carbohydrate substrates in the liver, ensuring adequate blood glucose levels during fasting.1
  • Lipid Metabolism: GCGR influences lipolysis in adipose tissue, mobilizing energy stores during metabolic stress.3
  • Ketogenesis: GCGR signaling promotes the production of ketone bodies in the liver, providing an alternative energy source during prolonged fasting.2
  • Amino Acid Catabolism: GCGR helps regulate amino acid metabolism in the liver, maintaining nitrogen balance and gluconeogenic substrate availability.4

GCGR’s Role in Disease and Drug Discovery

Given its central role in glucose regulation and metabolic homeostasis, GCGR is a promising therapeutic target for several metabolic disorders. Research and drug development efforts are focused on leveraging GCGR signaling to treat conditions such as:

  • Type 2 Diabetes: GCGR antagonists are being developed to lower blood glucose levels by reducing hepatic glucose production. Early studies suggest these agents improve glycemic control while moderately increasing circulating glucagon and GLP-1 levels.5
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging research highlights GCGR’s potential role in MASLD treatment. GCGR antagonists may help reduce fat accumulation in the liver and inflammation by modulating lipid metabolism.6
  • Obesity: GCGR agonists are under investigation for their ability to enhance energy expenditure and promote weight loss, making them attractive candidates for obesity management.3
  • Hyperaminoacidemia: GCGR’s regulation of amino acid metabolism has therapeutic implications for managing conditions characterized by elevated plasma amino acid levels.4

INDIGO’s GCGR Reporter Assays

INDIGO Biosciences offers advanced GCGR Reporter Assays to facilitate research into GCGR signaling and accelerate drug discovery efforts. Our assays feature an all-inclusive luciferase reporter system, including engineered, pre-transfected GCGR Reporter Cells, optimized media, a reference agonist, luciferase detection reagent, and a cell culture-ready assay plate. INDIGO can also perform GCGR assays in our lab as a service for researchers.

INDIGO’s cell-based reporter assays allow scientists to evaluate compounds for their ability to regulate GCGR activity in agonist, inverse-agonist, or antagonist modes. The receptor’s binding to its ligand controls the expression of the luciferase reporter gene, enabling researchers to correlate luciferase activity with receptor activation. This system provides a robust platform for generating high-quality, reproducible data.

INDIGO Biosciences provides comprehensive technical support to assist researchers in implementing and interpreting GCGR reporter assay results. Contact us today to learn more about INDIGO’s GCGR reporter assay kits and our screening capabilities!

 

Works Cited

  1. Jiang, G., & Zhang, B. B. (2003). Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology and Metabolism, 284(4), E671–E678.
  2. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010 Dec;6(12):689-97.
  3. Lasher, A & Srivastava, Hemant & Sun, Liou. (2022). Insights into the Role of Glucagon Receptor Signaling in Metabolic Regulation from Pharmacological Inhibition and Tissue-Specific Knockout Models. Biomedicines. 10. 1907.
  4. Kazda, C. M., Ding, Y., Kelly, et al. (2016). Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients with Type 2 Diabetes. Diabetes Care, 39(7), 1241–1249.
  5. Gu, W., Yan, H., Winters, K. A., et al. (2009). Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control , with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther. 2009 Dec;331(3):871-81.
  6. Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N. and Hardy, T. A. (2017), Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes. Diabetes Obes Metab. Accepted Author Manuscript.